| Ki‐67 expression as a prognostic factor in diffuse large B‐cell lymphoma patients treated with rituximab plus CHOP DH Yoon, DR Choi, HJ Ahn, S Kim, DH Lee, SW Kim, BH Park, SO Yoon, ... European journal of haematology 85 (2), 149-157, 2010 | 82 | 2010 |
| Prognostic impact of TTF-1 expression in non-squamous non-small-cell lung cancer: a meta-analysis JH Kim, HS Kim, BJ Kim, B Han, DR Choi, JH Kwon Journal of Cancer 9 (22), 4279, 2018 | 50 | 2018 |
| Multicenter, cross-sectional observational study of the impact of neuropathic pain on quality of life in cancer patients SY Oh, SW Shin, SJ Koh, SB Bae, H Chang, JH Kim, HJ Kim, YS Hong, ... Supportive Care in Cancer 25, 3759-3767, 2017 | 42 | 2017 |
| Sunitinib as a second-line therapy for advanced GISTs after failure of imatinib: relationship between efficacy and tumor genotype in Korean patients DH Yoon, MH Ryu, BY Ryoo, M Beck, DR Choi, Y Cho, JL Lee, ... Investigational new drugs 30, 819-827, 2012 | 38 | 2012 |
| Nilotinib in patients with GIST who failed imatinib and sunitinib: importance of prior surgery on drug bioavailability K Kim, MH Ryu, C Yoo, BY Ryoo, DR Choi, HM Chang, JL Lee, MY Beck, ... Cancer chemotherapy and pharmacology 68, 285-291, 2011 | 38 | 2011 |
| Impact of clinical, cytogenetic, and molecular profiles on long-term survival after transplantation in patients with chronic myelomonocytic leukemia J Woo, DR Choi, BE Storer, C Yeung, AB Halpern, RB Salit, ML Sorror, ... Haematologica 105 (3), 652, 2020 | 31 | 2020 |
| Predictors of high score patient-reported barriers to controlling cancer pain: a preliminary report JH Kwon, SY Oh, G Chisholm, JA Lee, JJ Lee, KW Park, SH Nam, ... Supportive Care in Cancer 21, 1175-1183, 2013 | 31 | 2013 |
| Efficacy and tolerability of ramucirumab monotherapy or in combination with paclitaxel in gastric cancer patients from the Expanded Access Program Cohort by the Korean Cancer … M Jung, MH Ryu, DY Oh, M Kang, DY Zang, IG Hwang, KW Lee, KH Kim, ... Gastric Cancer 21, 819-830, 2018 | 30 | 2018 |
| Multicenter phase II study of oxaliplatin, irinotecan, and S-1 as first-line treatment for patients with recurrent or metastatic biliary tract cancer C Yoo, B Han, HS Kim, K Kim, D Kim, JH Jeong, JL Lee, TW Kim, JH Kim, ... Cancer Research and Treatment: Official Journal of Korean Cancer Association …, 2018 | 29 | 2018 |
| Expression and prognostic significance of microRNAs in Korean patients with myelodysplastic syndrome Y Choi, EH Hur, JH Moon, BK Goo, DR Choi, JH Lee The Korean Journal of Internal Medicine 34 (2), 390, 2019 | 21 | 2019 |
| Phase II study of docetaxel, oxaliplatin, and S-1 therapy in patients with metastatic gastric cancer HS Kim, MH Ryu, DY Zang, BY Ryoo, DH Yang, JW Cho, MS Lim, MJ Kim, ... Gastric Cancer 19, 579-585, 2016 | 21 | 2016 |
| A phase II study of pemetrexed and carboplatin as a salvage therapy for platinum-pretreated patients with non-small cell lung cancer HS Kim, GW Lee, JH Kim, HY Kim, JH Kwon, HH Song, HJ Kim, JY Jung, ... Lung Cancer 70 (1), 71-76, 2010 | 21 | 2010 |
| Irinotecan, leucovorin and 5‑fluorouracil (modified FOLFIRI) as salvage chemotherapy for frail or elderly patients with advanced gastric cancer JH Kim, HS Kim, A Han, IH Moh, DC Chung, DR Choi, HJ Jang, JB Kim, ... Oncology Letters 4 (4), 751-754, 2012 | 20 | 2012 |
| Phase II trial of gemcitabine and S-1 for patients with advanced pancreatic cancer H Song, B Han, CK Park, JH Kim, JY Jeon, IG Kim, HJ Kim, JY Jung, ... Cancer chemotherapy and pharmacology 72, 845-852, 2013 | 18 | 2013 |
| Phase II study of weekly carboplatin and irinotecan as first-line chemotherapy for patients with advanced non-small cell lung cancer HS Kim, JH Kim, B Kim, HC Choi, JH Kwon, DR Choi Cancer chemotherapy and pharmacology 71, 1591-1597, 2013 | 17 | 2013 |
| Establishment and characterization of hypomethylating agent-resistant cell lines, MOLM/AZA-1 and MOLM/DEC-5 EH Hur, SH Jung, BK Goo, J Moon, Y Choi, DR Choi, YJ Chung, JH Lee Oncotarget 8 (7), 11748, 2017 | 15 | 2017 |
| Phase II study of oxaliplatin, irinotecan and S-1 therapy in patients with advanced gastric cancer: the Korean Cancer Study Group ST14-11 HS Kim, MH Ryu, DY Zang, SR Park, B Han, WK Kang, SY Rha, M Jung, ... Gastric Cancer 21, 802-810, 2018 | 14 | 2018 |
| Phase II study of gemcitabine and S-1 combination chemotherapy in patients with metastatic biliary tract cancer HS Kim, HY Kim, DY Zang, HS Oh, JY Jeon, JW Cho, CK Park, JH Kim, ... Cancer Chemotherapy and Pharmacology 75, 711-718, 2015 | 14 | 2015 |
| Erlotinib in first-line therapy for non-small cell lung cancer: a prospective phase II study DR Choi, DH Lee, CM Choi, SW Kim, C Suh, JS Lee Anticancer research 31 (10), 3457-3462, 2011 | 14 | 2011 |
| Single-lesion measurement per organ for assessing tumor response in advanced gastric cancer HS Kim, JW Kim, JH Kim, DR Choi, A Han, MJ Kim, BC Kim, DY Zang Oncology 88 (2), 69-75, 2015 | 13 | 2015 |
